AIM ImmunoTech: Kelvest I LP returns 14,574 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. director Ted D. Kellner reported entity-held dispositions to the issuer on November 18, 2026. Kelvest I LP returned 14,574 shares at $0.1360 each, leaving 19,714 shares. Beta Fund Investment Club returned 2,702 shares and Kellner’s profit-sharing plan returned 250 shares, each at $0.1360; both reported zero shares afterward. Kellner is the Beta Fund manager and investor, but disclaims beneficial ownership except for his pecuniary interest; he is trustee of the plan and manager of Kelvest’s general partner.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Common Stock F1 | 14,574 | $0.136 | $2K |
| Disposition | Common Stock F2 | 2,702 | $0.136 | $367.47 |
| Disposition | Common Stock F3 | 250 | $0.136 | $34.00 |
Footnotes (3)
- F1. Shares held by Kelvest I LP, for which the reporting person serves as Manager of T&M Partners LLC, General Partner of Kelvest I LP.
- F2. Shares held by the Beta Fund Investment Club, for which the reporting person serves as the manager and is an investor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F3. Shares held by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which the reporting person serves as trustee.
Key Figures
Key Terms
pecuniary interest regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.